Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients

• Tipo: Artigo em Revista Científica Internacional
• Data: 2008

Autores

Elisio Costa (Autor) FFUP; Brian J G Pereira (Autor) Outra; Petronila Rocha Pereira (Autor) Outra; Susana Rocha (Autor) FFUP; Flavio Reis (Autor) Outra; Elisabeth Castro (Autor) Outra; Frederico Teixeira (Autor) Outra; Vasco Miranda (Autor) Outra; Maria do Sameiro Faria (Autor) Outra; Alfredo Loureiro (Autor) Outra; Alexandre Quintanilha (Autor) ICBAS; Luis Belo (Autor) FFUP; Alice Santos Silva (Autor) FFUP

Revista

Título: American Journal of Nephrology

Vol. 28 Nº 4

Páginas: 677-683

ISSN: 0250-8095

Editora: Karger

Indexação

ISI Web of Knowledge - 36 Citações

ISI Web of Science

Scopus - 35 Citações

Classificação Científica

FOS: Ciências médicas e da saúde > Medicina clínica

CORDIS: Ciências da Saúde

Outras Informações

ID Authenticus: P-004-2G1

DOI: 10.1159/000121478

Resumo (PT): The aim of our study was to assess possible relations between prohepcidin, iron status and inflammatory markers in hemodialysis (HD) patients, as well as its association with resistance to recombinant human erythropoietin (rhEPO) therapy. Fifty HD patients and 25 healthy controls were enrolled in the study. Among HD patients, 25 were non-responders and 25 were responders to rhEPO therapy. Complete blood cell count, reticulocyte count, and circulating levels of ferritin, iron, transferrin saturation, C-reactive protein (CRP), soluble interleukin (IL)-2 receptor (s-IL2R), soluble transferrin receptor (s-TfR), IL-6 and prohepcidin were measured in all patients and controls. HD patients showed higher circulating levels of ferritin, s-TfR, CRP, IL-6, s-IL2R and prohepcidin, and lower levels of transferrin compared to healthy controls. Higher levels of s-TfR, CRP and lower levels prohepcidin were observed among non-responders compared to responders. Prohepcidin levels correlated negatively with s-TfR and reticulocyte count. The weekly rhEPO/kg dose was found to be positively correlated with CRP, hemoglobin and s-TfR. In conclusion, our data show that a close interaction exists between inflammation, iron status and prohepcidin serum levels that ultimately regulate intracellular iron availability. Prohepcidin and s-TfR, together with CRP, may prove to be good markers of resistance to rhEPO therapy in HD patients. <br> <br> Key Words: Erythropoietin Hepcidin Iron Iron metabolism Prohepcidin Resistance rhEPO <br> <br>

Abstract (EN): The aim of our study was to assess possible relations between prohepcidin, iron status and inflammatory markers in hemodialysis (HD) patients, as well as its association with resistance to recombinant human erythropoietin (rhEPO) therapy. Fifty HD patients and 25 healthy controls were enrolled in the study. Among HD patients, 25 were non-responders and 25 were responders to rhEPO therapy. Complete blood cell count, reticulocyte count, and circulating levels of ferritin, iron, transferrin saturation, C-reactive protein (CRP), soluble interleukin (IL)-2 receptor (s-IL2R), soluble transferrin receptor (s-TfR), IL-6 and prohepcidin were measured in all patients and controls. HD patients showed higher circulating levels of ferritin, s-TfR, CRP, IL-6, s-IL2R and prohepcidin, and lower levels of transferrin compared to healthy controls. Higher levels of s-TfR, CRP and lower levels prohepcidin were observed among non-responders compared to responders. Prohepcidin levels correlated negatively with s-TfR and reticulocyte count. The weekly rhEPO/kg dose was found to be positively correlated with CRP, hemoglobin and s-TfR. In conclusion, our data show that a close interaction exists between inflammation, iron status and prohepcidin serum levels that ultimately regulate intracellular iron availability. Prohepcidin and s-TfR, together with CRP, may prove to be good markers of resistance to rhEPO therapy in HD patients. Copyright (C) 2008 S. Karger AG, Basel.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 7